COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Entos Pharmaceuticals develops nucleic acid genetic medicines using its Fusogenix PLV proteolipid vehicle—FAST protein–mediated direct fusion delivery of RNA, DNA, and gene‑editing therapies—and operates R&D, clinical, and GMP programs.
